This is an open-label, randomized, single-dose, parallel group study. The objectives of this
study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN)
prolonged release (PR) tablet 5/2.5 mg (OXN 5/2.5) and 20/10 mg (OXN 20/10) in Chinese
patients with moderate to severe chronic non-malignant pain.